Agency Information Collection Activities; Submission for Office of Management and Budget Review; Comment Request; Animal Drug User Fee Cover Sheet, Form 3546, 7866-7867 [2011-3167]

Download as PDF 7866 Federal Register / Vol. 76, No. 29 / Friday, February 11, 2011 / Notices DEPARTMENT OF HEALTH AND HUMAN SERVICES Dated: February 7, 2011. Leslie Kux, Acting Assistant Commissioner for Policy. Food and Drug Administration [FR Doc. 2011–3031 Filed 2–10–11; 8:45 am] In compliance with 44 U.S.C. 3507, FDA has submitted the following proposed collection of information to OMB for review and clearance. SUPPLEMENTARY INFORMATION: BILLING CODE 4160–01–P [Docket No. 2010–N–0066] Agency Information Collection Activities; Announcement of Office of Management and Budget Approval; Human Tissue Intended for Transplantation AGENCY: Food and Drug Administration, HHS. ACTION: Notice. The Food and Drug Administration (FDA) is announcing that a collection of information entitled ‘‘Human Tissue Intended for Transplantation’’ has been approved by the Office of Management and Budget (OMB) under the Paperwork Reduction Act of 1995. SUMMARY: FOR FURTHER INFORMATION CONTACT: Johnny Vilela, Office of Information Management, Food and Drug Administration, 1350 Piccard Dr., PI50– 400B, Rockville, MD 20850, (301) 796– 7651, Juanmanuel.Vilela@fda.hhs.gov. In the Federal Register of August 2, 2010 (75 FR 45127), the Agency announced that the proposed information collection had been submitted to OMB for review and clearance under 44 U.S.C. 3507. An Agency may not conduct or sponsor, and a person is not required to respond to, a collection of information unless it displays a currently valid OMB control number. OMB has now approved the information collection and has assigned OMB control number 0910–0302. The approval expires on January 31, 2014. A copy of the supporting statement for this information collection is available on the Internet at https://www.reginfo.gov/ public/do/PRAMain. SUPPLEMENTARY INFORMATION: Animal Drug User Fee Cover Sheet; FDA Form 3546—(OMB Control Number 0910–0539)—Extension DEPARTMENT OF HEALTH AND HUMAN SERVICES Food and Drug Administration [Docket No. FDA–2010–N–0600] Agency Information Collection Activities; Submission for Office of Management and Budget Review; Comment Request; Animal Drug User Fee Cover Sheet, Form 3546 AGENCY: Food and Drug Administration, HHS. ACTION: Notice. The Food and Drug Administration (FDA) is announcing that a proposed collection of information has been submitted to the Office of Management and Budget (OMB) for review and clearance under the Paperwork Reduction Act of 1995. DATES: Fax written comments on the collection of information by March 14, 2011. ADDRESSES: To ensure that comments on the information collection are received, OMB recommends that written comments be faxed to the Office of Information and Regulatory Affairs, OMB, Attn: FDA Desk Officer, FAX: 202–395–7285, or e-mailed to oira_submission@omb.eop.gov. All comments should be identified with the OMB control number 0910–0539. Also include the FDA docket number found in brackets in the heading of this document. FOR FURTHER INFORMATION CONTACT: Johnny Vilela, Office of Information Management, Food and Drug Administration, 1350 Piccard Dr., PI50– 400B, Rockville, MD 20850, 301–796– 7651, Juanmanuel.vilela@fda.hhs.gov. SUMMARY: Under section 740 of the Federal Food, Drug, and Cosmetic Act (the FD&C Act) (21 U.S.C. 379j-12), as amended by the Animal Drug User Fee Act (ADUFA), FDA has the authority to assess and collect for certain animal drug user fees. Because the submission of user fees concurrently with applications and supplements is required, review of an application cannot begin until the fee is submitted. The types of fees that require a cover sheet are certain animal drug application fees and certain supplemental animal drug application fees. The cover sheet (FDA Form 3546) is designed to provide the minimum necessary information to determine whether a fee is required for the review of an application or supplement, to determine the amount of the fee required, and to assure that each animal drug user fee payment and each animal drug application for which payment is made is appropriately linked to the payment that is made. The form, when completed electronically, will result in the generation of a unique payment identification number used in tracking the payment. FDA will use the information collected to initiate administrative screening of new animal drug applications and supplements to determine if payment has been received. In the Federal Register of November 29, 2010 (75 FR 73103), FDA published a 60-day notice requesting public comment on the proposed collection of information. No comments were received. FDA estimates the burden of this collection of information as follows: TABLE 1—ESTIMATED ANNUAL REPORTING BURDEN 1 FD&C Act Section amended by ADUFA No. of respondents Annual frequency per response Total annual responses Hours per response Total hours 740(a)(1) FDA Form 3546 (Cover Sheet) ........................... 76 1 76 1 76 ........................ ........................ ........................ ........................ 76 jlentini on DSKJ8SOYB1PROD with NOTICES Total .............................................................................. 1 There are no capital costs or operating and maintenance costs associated with this collection of information. Respondents to this collection of information are new animal drug applicants or manufacturers. Based on FDA’s database system, there are an VerDate Mar<15>2010 18:55 Feb 10, 2011 Jkt 223001 estimated 140 manufacturers of products or sponsors of new animal drugs potentially subject to ADUFA. However, not all manufacturers or PO 00000 Frm 00060 Fmt 4703 Sfmt 4703 sponsors will have any submissions in a given year and some may have multiple submissions. The total number of annual responses is based on the E:\FR\FM\11FEN1.SGM 11FEN1 Federal Register / Vol. 76, No. 29 / Friday, February 11, 2011 / Notices number of submissions received by FDA in fiscal year 2008. The estimated hours per response are based on past FDA experience with the various submissions. The hours per response are based on the average of these estimates. Dated: February 8, 2011. Leslie Kux, Acting Assistant Commissioner for Policy. [FR Doc. 2011–3167 Filed 2–10–11; 8:45 am] BILLING CODE 4160–01–P DEPARTMENT OF HEALTH AND HUMAN SERVICES National Institutes of Health Proposed Collection; Comment Request; Cancer Biomedical Informatics Grid® (caBIG®) Support Service Provider (SSP) Program (NCI) In compliance with the requirement of Section 3506(c)(2)(A) of the Paperwork Reduction Act of 1995, for opportunity for public comment on proposed data collection projects, the National Cancer Institute (NCI), the National Institutes of Health (NIH) will publish periodic summaries of proposed projects to be submitted to the Office of Management and Budget (OMB) for review and approval. SUMMARY: Proposed Collection: Title: cancer Biomedical Informatics Grid ® (caBIG ®) Support Service Provider (SSP) Program (NCI). Type of Information Collection Request: Existing Collection in Use Without an OMB Number. Need and Use of Information Collection: The NCI Center for Biomedical Informatics and Information Technology (CBIIT) launched the enterprise phase of the caBIG ® initiative in early 2007 with an emphasis on widespread institutional adoption of the program and tools. This emphasis on adoption has generated an expanding community with diverse needs for support, which are met through the resources available through the caBIG ® Enterprise Support Network (ESN), including the caBIG ® Support Service Provider (SSP) Program. The caBIG ® SSPs provide caBIG ® end-users with the freedom to match what caBIG ® has to offer to their unique organizational goals and needs, so having this customized support option available is critically important to advancing the goals of the caBIG ® program. caBIG ® SSP applicants are evaluated against well-defined criteria published in the SSP Program Announcement and must successfully demonstrate that they have the technical capabilities, staffing and scalability, geographic coverage (when applicable), and the domain expertise in 7867 biomedicine to effectively serve caBIG ® users. The information submitted by SSP applicants enables NCI to determine whether such applicants are qualified to enter into trademark license negotiations with NCI to use the caBIG ® trademarks in connection with their services and become designated as caBIG ® SSPs. Thus, the collection of information from SSP applicants is critical to both ensuring that the goals and objectives of the caBIG ® program will be maintained and furthered by the organizations designated as SSPs and facilitating NCI’s ability to exercise appropriate stewardship of the caBIG ® trademarks. Sections 410 and 411 of the Public Health Service Act (42 U.S.C. 285 and 285a) authorize the collection of the information. Frequency of Response: once for the applicants. caBIG ® SSP applications are accepted on a rolling basis and reviewed several times a year. Affected Public: Private sector including Business or other for-profits and not-forprofit organizations and institutions. Type of Respondents: Technical representatives of commercial, academic or not-for-profit organizations. The annual reporting burden is estimated at 360 hours. There are no Capital Costs, Operating Costs, and/or Maintenance Costs to report. A.12—1 ESTIMATES OF ANNUAL BURDEN HOURS Number of respondents Type of respondents Frequency of response Average time per response (minutes/hour) Annual burden hours 336 360 14 1 Nonprofit Organizations ................................................................................... 1 1 1440/60 (24 hours) 1440/60 (24 hours) Totals ........................................................................................................ jlentini on DSKJ8SOYB1PROD with NOTICES Commercial Organizations .............................................................................. 15 ........................ ........................ Request for Comments: Written comments and/or suggestions from the public and affected agencies are invited on one or more of the following points: (1) Evaluate whether the proposed collection of information is necessary for the proper performance of the function of the agency, including whether the information will have practical utility; (2) Evaluate the accuracy of the agency’s estimate of the burden of the proposed collection of information, including the validity of the methodology and assumptions used; (3) Enhance the quality, utility, and clarity of the information to be collected; and (4) Minimize the burden of the collection of information on those who are to respond, including the use VerDate Mar<15>2010 18:55 Feb 10, 2011 Jkt 223001 of appropriate automated, electronic, mechanical, or other technological collection techniques or other forms of information technology. To request more information on the proposed project or to obtain a copy of the data collection plans and instruments, contact John Speakman, NCI CBIIT Chief Program Officer, Center for Biomedical Informatics and Information Technology, National Cancer Institute, NIH, DHHS, 2115 E. Jefferson Street, Suite 6000, Rockville, MD 20892 or call non-toll-free number 301–451–8786 or e-mail your request, including your address to: john.speakman@nih.gov. FOR FURTHER INFORMATION CONTACT: PO 00000 Frm 00061 Fmt 4703 Sfmt 9990 24 Comments Due Date: Comments regarding this information collection are best assured of having their full effect if received within 60 days of the date of this publication. Dated: February 4, 2011. Vivian Horovitch-Kelley, NCI Project Clearance Liaison, National Institutes of Health. [FR Doc. 2011–3144 Filed 2–10–11; 8:45 am] BILLING CODE 4140–01–P E:\FR\FM\11FEN1.SGM 11FEN1

Agencies

[Federal Register Volume 76, Number 29 (Friday, February 11, 2011)]
[Notices]
[Pages 7866-7867]
From the Federal Register Online via the Government Printing Office [www.gpo.gov]
[FR Doc No: 2011-3167]


-----------------------------------------------------------------------

DEPARTMENT OF HEALTH AND HUMAN SERVICES

Food and Drug Administration

[Docket No. FDA-2010-N-0600]


Agency Information Collection Activities; Submission for Office 
of Management and Budget Review; Comment Request; Animal Drug User Fee 
Cover Sheet, Form 3546

AGENCY: Food and Drug Administration, HHS.

ACTION: Notice.

-----------------------------------------------------------------------

SUMMARY: The Food and Drug Administration (FDA) is announcing that a 
proposed collection of information has been submitted to the Office of 
Management and Budget (OMB) for review and clearance under the 
Paperwork Reduction Act of 1995.

DATES: Fax written comments on the collection of information by March 
14, 2011.

ADDRESSES: To ensure that comments on the information collection are 
received, OMB recommends that written comments be faxed to the Office 
of Information and Regulatory Affairs, OMB, Attn: FDA Desk Officer, 
FAX: 202-395-7285, or e-mailed to oira_submission@omb.eop.gov. All 
comments should be identified with the OMB control number 0910-0539. 
Also include the FDA docket number found in brackets in the heading of 
this document.

FOR FURTHER INFORMATION CONTACT: Johnny Vilela, Office of Information 
Management, Food and Drug Administration, 1350 Piccard Dr., PI50-400B, 
Rockville, MD 20850, 301-796-7651, Juanmanuel.vilela@fda.hhs.gov.

SUPPLEMENTARY INFORMATION: In compliance with 44 U.S.C. 3507, FDA has 
submitted the following proposed collection of information to OMB for 
review and clearance.

Animal Drug User Fee Cover Sheet; FDA Form 3546--(OMB Control Number 
0910-0539)--Extension

    Under section 740 of the Federal Food, Drug, and Cosmetic Act (the 
FD&C Act) (21 U.S.C. 379j-12), as amended by the Animal Drug User Fee 
Act (ADUFA), FDA has the authority to assess and collect for certain 
animal drug user fees. Because the submission of user fees concurrently 
with applications and supplements is required, review of an application 
cannot begin until the fee is submitted. The types of fees that require 
a cover sheet are certain animal drug application fees and certain 
supplemental animal drug application fees. The cover sheet (FDA Form 
3546) is designed to provide the minimum necessary information to 
determine whether a fee is required for the review of an application or 
supplement, to determine the amount of the fee required, and to assure 
that each animal drug user fee payment and each animal drug application 
for which payment is made is appropriately linked to the payment that 
is made. The form, when completed electronically, will result in the 
generation of a unique payment identification number used in tracking 
the payment. FDA will use the information collected to initiate 
administrative screening of new animal drug applications and 
supplements to determine if payment has been received.
    In the Federal Register of November 29, 2010 (75 FR 73103), FDA 
published a 60-day notice requesting public comment on the proposed 
collection of information. No comments were received.
    FDA estimates the burden of this collection of information as 
follows:

                                                     Table 1--Estimated Annual Reporting Burden \1\
--------------------------------------------------------------------------------------------------------------------------------------------------------
                                                                                           Annual
                 FD&C Act Section amended by ADUFA                        No. of       frequency per     Total annual      Hours per       Total hours
                                                                       respondents        response        responses         response
--------------------------------------------------------------------------------------------------------------------------------------------------------
740(a)(1) FDA Form 3546 (Cover Sheet)..............................              76                1               76                1               76
                                                                    ------------------------------------------------------------------------------------
    Total..........................................................  ...............  ...............  ...............  ...............              76
--------------------------------------------------------------------------------------------------------------------------------------------------------
\1\ There are no capital costs or operating and maintenance costs associated with this collection of information.

    Respondents to this collection of information are new animal drug 
applicants or manufacturers. Based on FDA's database system, there are 
an estimated 140 manufacturers of products or sponsors of new animal 
drugs potentially subject to ADUFA. However, not all manufacturers or 
sponsors will have any submissions in a given year and some may have 
multiple submissions. The total number of annual responses is based on 
the

[[Page 7867]]

number of submissions received by FDA in fiscal year 2008. The 
estimated hours per response are based on past FDA experience with the 
various submissions. The hours per response are based on the average of 
these estimates.

    Dated: February 8, 2011.
Leslie Kux,
Acting Assistant Commissioner for Policy.
[FR Doc. 2011-3167 Filed 2-10-11; 8:45 am]
BILLING CODE 4160-01-P
This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.